Medios AG Adjusts 2026 Earnings Guidance Amid Revenue Growth

Medios AG, a leader in specialty pharmaceuticals, has revised its financial outlook for 2026. The company reported a record-breaking Group revenue of €1.075 billion in the first half of the year, up from €991.7 million in the previous year. Despite this, Medios adjusted its EBITDA pre¹ guidance down to €88-92 million, compared to an earlier range of €94-102 million. Revenue projections, however, have been increased from €2.0-2.12 billion to €2.1-2.16 billion.

The revised earnings forecast is attributed to continued price declines in high-margin Pharmaceutical Supply products and tightening regulations on medical cannabis in Germany. These factors have outweighed expected revenue gains in the latter half of the year. Efforts to mitigate these effects include cost-cutting measures and efficiency improvements.

CEO Thomas Meier stated that while growth continues, price pressures and legal changes necessitate a focus on profitable areas. Further details will be shared in upcoming conferences and reports.